$BAX

Citigroup maintained a Neutral rating for Baxter International (BAX) but lowered its price target to $27.00 from $28.00. Baxter's GF Value™ is $31.70, suggesting a 23.6% undervaluation, but the company is currently unprofitable with a P/S ratio of 8.47. Baxter's GF Score™ is 70/100, indicating moderate financial health and performance.

Baxter (BAX) reported Q2 revenue of $2.96B, up 5.3% YoY, beating estimates. LeMaitre (LMAT) reported $70.38M, up 9.6% YoY, missing estimates. STERIS (STE) reported $1.49B, up 7.3% YoY, in line with estimates. Lantheus (LNTH) reported $388.2M, up 2.7% YoY, beating estimates. Stocks are down since reporting.

Baxter International (BAX) has underperformed rival Becton, Dickinson (BDX) with a 22.8% gain over 52 weeks but lagged on a YTD basis with an 18.3% increase. Analysts give BAX a consensus 'Hold' rating, with a mean price target of $27, implying an 18.4% upside from current levels.

Otsuka ICU Medical recalled a lot of 0.9% Sodium Chloride Injection due to a mix-up with highly concentrated Potassium Chloride. Baxter International recalled two lots of the same product over potential fiberglass contamination. Both recalls were issued by the FDA.

Baxter and B. Braun recalled IV saline bags due to fiberglass and rust particles. Baxter recalled sodium chloride, sodium citrate, and dextrose lots, while B. Braun recalled sodium chloride. No injuries reported, but particles pose serious risks if they enter the bloodstream. Baxter's North Cove plant supplies 60% of U.S. IV fluids, raising concerns about potential shortages. The FDA has not yet classified these recalls.

Baxter International Inc. (BAX) raised its 2026 outlook despite margin pressure, citing strong Q2 growth. The company continues to work with regulators and faces potential customer uncertainty. Becton, Dickinson and Company (BDX) and ICU Medical, Inc. (ICUI) also compete in the infusion technology market. BAX has a Zacks Rank #3 (Hold), with a Value Score of B, Growth Score of B, and VGM Score of B, but a Momentum Score of C.

Baxter International recalled two lots of 0.9% Sodium Chloride injection and one lot of Anticoagulant Sodium Citrate Solution due to potential fiberglass particles, according to the FDA. The recalls were issued on Aug. 25 and 26, with distribution dates in July. Baxter stated no adverse events have been reported as of Sept. 3, 2026, and they are working with the FDA.

Baxter International (BAX) appointed John Rogers as CFO, with CEO Andrew Hider temporarily assuming CFO duties. Rogers brings cross-industry experience, potentially influencing capital allocation and reporting. Baxter aims for $12.4B revenue and $788.3M earnings by 2029, requiring 2.8% yearly revenue growth. The company recently launched a $600M tender offer for longer-dated notes, amending its credit agreement. Investors focus on margin stabilization and leverage.

Baxter International recalled two lots of 0.9% sodium chloride injections due to potential fiberglass contamination. The affected products are in 500ml Viaflex containers with lot numbers Y495523 and Y495523A, distributed to 14 U.S. states. No injuries or illnesses have been reported as of August 25, according to the company.

Baxter International Inc. has appointed John Rogers as Chief Financial Officer, effective October 1, 2026. Rogers brings extensive experience from roles at Smith+Nephew, WPP, and Sainsbury's. He will focus on stabilizing the business and improving execution. Baxter is a global healthcare and medical technology company.